Speakers
Alejandra Raimondi
Vice President Biological Sciences
Epizyme
Day One
Wednesday, July 27
9:45 am | Identifying Novel Targets for Epigenetic Drug Discovery & Development to Accelerate Pipeline Decision Making
9:00 am | PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years?
Alon Goren
Assistant Professor
University of San Diego California (UCSD)
Day One
Wednesday, July 27
10:15 am | Improvements to ChIP-seq by Using Automation & Spike-in Normalization Approaches
Day Two
Thursday, July 28
2:00 pm | PANEL DISCUSSION: Let’s Talk About Epigenetic Drug Resistance
Asad Taherbhoy
Director of Drug Discovery
Foghorn Therapeutics
Day One
Wednesday, July 27
9:00 am | PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years?
Day Two
Thursday, July 28
10:00 am | Targeting Transcription Factor-BAF Interactions in Cancer
Ayman El-Guindy
Chief Scientific Officer
Viracta Therapeutics
Day Two
Thursday, July 28
12:00 pm | Activation of Latent Oncogenic Viruses as a Form of Targeted Cancer Therapy
Claes Wahlestedt
Associate Dean & Center Director for Therapeutic Innovation; Chief Scientific Officer
University of Miami Miller School of Medicine; Epigenetix
Day One
Wednesday, July 27
11:45 am | Exploring the Discovery & Development of an Oral Trispecific Cancer Drug
Day Two
Thursday, July 28
2:00 pm | PANEL DISCUSSION: Let’s Talk About Epigenetic Drug Resistance
David Bumcrot
Chief Scientific Officer
CAMP4 Therapeutics
Day Two
Thursday, July 28
11:00 am | Regulating Gene Expression by Targeting Regulatory RNAs: A Novel Therapeutic Approach
Henry Long
Scientific Director Center for Functional Cancer Epigenetics
Dana Farber Cancer Institute
Day Two
Thursday, July 28
1:30 pm | Studying Neuroendocrine Transdifferentiation as a Mechanism of Drug Resistance
Isaac Klein
Chief Scientific Officer
Dewpoint Therapeutics
Day One
Wednesday, July 27
8:55 am | Chair Opening Remarks
Jacob Berchuck
Medical Oncologist
Dana Farber Cancer Institute
Day Two
Thursday, July 28
9:30 am | Opportunities for non-invasive cancer detection and classification through epigenetic analysis of cell-free DNA
Kirk Tanner
Chief Scientific Officer
National Brain Tumor Society
Day One
Wednesday, July 27
1:45 pm | Detailing the Opportunities for Epigenetic Drug Discovery & Development in CNS Tumors to Inform Pipeline Decision Making
Kristen JensenPergakes
Associate Research Fellow
Pfizer
Day One
Wednesday, July 27
11:15 am | SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Laura Poling
Director of Biology
C4 Therapeutics
Day Two
Thursday, July 28
11:30 am | CFT8634, a Potent & Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers
Matthew Oser
Assistant Professor of Medicine Dana Farber Cancer Institute
Harvard Medical School
Day One
Wednesday, July 27
3:15 pm | Spearheading CRISPR/Cas9 Screening to Identity Genes Necessary for LSD1 to Maintain the Neuroendocrine Identify of Small Cell Lung Cancer
Paloma Cejas
Assistant Director for Center for Functional Cancer Epigenetics
Dana-Farber Cancer Institute
Day Two
Thursday, July 28
9:00 am | Evaluating Current Exploration into the Single Cell Space to Precisely Understand Epigenetic Behaviour
2:00 pm | PANEL DISCUSSION: Let’s Talk About Epigenetic Drug Resistance
Peter Atadja
Scientific Co-Founder
K36 Therapeutics
Day One
Wednesday, July 27
9:00 am | PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years?
Philipp Mews
Co-Founder
EpiVario
Day One
Wednesday, July 27
2:45 pm | Developing Small-Molecule Drugs for Epigenetic Treatments of Psychiatric Disorders
Rich Bennett
Assistant Professor
University of Florida
Day One
Wednesday, July 27
1:15 pm | Leveraging CRISPR: Identification of Essential Proliferation & Trametinib Resistance Mechanisms in Uveal Melanoma
9:00 am | PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years?
Shikhar Sharma
Research Fellow
Pfizer
Day Two
Thursday, July 28
2:45 pm | Translating Established Targets: Potent anti-Tumor Activity of a KAT6A/KAT6B Inhibitor PF-9363/CTx-648 in KAT6A dysregulated ER+ Breast Cancer
Steven M. Fruchtman
President & Chief Executive Officer
Onconova Therapeutics
Day Two
Thursday, July 28